<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref033">
 <label>[33]</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Ashe</surname>
   <given-names>KM</given-names>
  </string-name>, 
  <string-name>
   <surname>Budman</surname>
   <given-names>E</given-names>
  </string-name>, 
  <string-name>
   <surname>Bangari</surname>
   <given-names>DS</given-names>
  </string-name>, 
  <string-name>
   <surname>Siegel</surname>
   <given-names>CS</given-names>
  </string-name>, 
  <string-name>
   <surname>Nietupski</surname>
   <given-names>JB</given-names>
  </string-name>, 
  <string-name>
   <surname>Wang</surname>
   <given-names>B</given-names>
  </string-name>, 
  <string-name>
   <surname>Desnick</surname>
   <given-names>RJ</given-names>
  </string-name>, 
  <string-name>
   <surname>Scheule</surname>
   <given-names>RK</given-names>
  </string-name>, 
  <string-name>
   <surname>Leonard</surname>
   <given-names>JP</given-names>
  </string-name>, 
  <string-name>
   <surname>Cheng</surname>
   <given-names>SH</given-names>
  </string-name>, 
  <string-name>
   <surname>Marshall</surname>
   <given-names>J</given-names>
  </string-name> (
  <year>2015</year>) 
  <article-title>Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease</article-title>. 
  <source>Mol Med</source>
  <volume>21</volume>, 
  <fpage>389</fpage>â€“
  <lpage>399</lpage>.
  <pub-id pub-id-type="pmid">25938659</pub-id>
 </mixed-citation>
</ref>
